Diflucan is a Schedule H/P drug in many countries, requiring a prescription.

Its legacy is its role in making systemic antifungal therapy outpatient-friendly and accessible.

Diflucan is excreted in human milk, requiring careful risk-benefit analysis during lactation.

The legacy of Diflucan is its transformation of systemic fungal infection management from inpatient to often outpatient care.

The high oral bioavailability of Diflucan makes it exceptionally convenient for outpatient step-down therapy.

Fungal cell membrane alterations, like increased chitin, can contribute to resistance.

Prophylactic Diflucan is common in neutropenia, but its value depends on local epidemiology.

Diflucan is a critical part of the antifungal arsenal in resource-limited settings.

Diflucan is ineffective against Lomentospora prolificans.

Diflucan is often used in pediatric antifungal therapy with weight-based dosing.